Insights on Renal Profiles of Iraqi Patients With Type II Diabetes
DOI:
https://doi.org/10.32792/utq/utjsci/v12i1.1282Keywords:
diabetic nephropathy, Diabetes mellitus, GFR, Urea, creatinineAbstract
Diabetic kidney disease, also known as diabetic nephropathy, is a serious complication that affects around 40% of individuals with diabetes. It stands as the primary cause of chronic kidney disease (CKD) on a global scale. There is an urgent need for widespread innovation to improve health outcomes for patients with diabetic kidney disease, and this will involve predicting the prevalence of renal impairment in diabetic patients.800 patients (312 males and 488 females) with Diabetes Mellitus Type II were enrolled in this cross-sectional study age range from (30-65). All patients were asked to fast for 8-12 hours, and All routine investigating assays (FBG, lipid profile, RFT, HBA1c). eGFR determined by calculator program. The eGFR was classified according to National Kidney Found. The study indicates that hyperglycemia does not affect serum urea levels, so it may not be useful in evaluating renal function for DM. The decline in eGFR is linearly linked with an increased risk of Kidney disease (End Stage. Once the progressive eGFR reduction has commenced, it is crucial to effectively manage the disease process driving this decline. The glomerular filtration rate (GFR) serves as the cornerstone for many of the kidney's regulatory functions and is widely regarded as the most comprehensive indicator of renal function. We recommended that every request for blood creatinine concentration be computed, and an eGFR should be provided using the (CKD-EPI) method.
Received:2024-07-12
Revised:2024-08-04
Accepted:2024-08-10
References
[1] B. A. Abed, S. B. Al-AAraji, and I. N. Salman, "Estimation of Galanin hormone in patients with newly thyroid dysfunction in type 2 diabetes mellitus," Biochem. Cell. Arch, vol. 21, no. 1, pp. 1317-1321, 2021.
[2] H. Sundqvist, E. Heikkala, J. Jokelainen, G. Russo, I. Mikkola, and M. Hagnäs, "Association of renal function screening frequency with renal function decline in patients with type 2 diabetes: a real-world study in primary health care," BMC nephrology, vol. 23, no. 1, p. 356, 2022.
[3] J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, "Global estimates of the prevalence of diabetes for 2010 and 2030," Diabetes research and clinical practice, vol. 87, no. 1, pp. 4-14, 2010.
[4] L. O. Farhan, E. M. Taha, and A. M. Farhan, "A Case control study to determine Macrophage migration inhibitor, and N-telopeptides of type I bone collagen Levels in the sera of osteoporosis patients," Baghdad Science Journal, vol. 19, no. 4, pp. 0848-0848, 2022.
[5] E. A. Abass, B. A. Abed, and S. N. Mohsin, "Study Of Lysyl Oxidase-1 And Kidney Function In Sera Of Iraqi Patients With Diabetic Nephropathy," Biochem Cell Arch, vol. 21, no. 1, pp. 1129-1132, 2021.
[6] P. Persson, P. Hansell, and F. Palm, "Tubular reabsorption and diabetes‐induced glomerular hyperfiltration," Acta physiologica, vol. 200, no. 1, pp. 3-10, 2010.
[7] S. K. Mohammed, E. M. Taha, S. A. Muhi, and A.-Y. T. Hosbital, "PENTRAXIN3 AND NITRIC OXIDE-ASSOCIATED WITH AN ATHEROGENIC INDEX AND TYPE II DIABETES MELLITUS," Biochemical & Cellular Archives, vol. 20, no. 1, 2020.
[8] R. Urgiles, J. Pastuna, M. Gonzalez, and A. Alexis, "Type 2 diabetes mellitus and chronic complications," International Journal of Innovative Science & Research Technology, vol. 5, pp. 1906-1911, 2020.
[9] G. J. Kashtl, B. A. Abed, L. O. Farhan, I. Noori, and A. S. D. Salman, "Archive of SID. ir," 2023.
[10] L. O. Farhan, B. A. Abed, and A. Dawood, "Comparison study between adipsin levels in sera of Iraqi patients with diabetes and neuropathy," Baghdad Science Journal, vol. 20, no. 3, pp. 0726-0726, 2023.
[11] J. M. Buades et al., "Management of kidney failure in patients with diabetes mellitus: what are the best options?," Journal of Clinical Medicine, vol. 10, no. 13, p. 2943, 2021.
[12] M. C. Thomas, M. E. Cooper, and P. Zimmet, "Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease," Nature Reviews Nephrology, vol. 12, no. 2, pp. 73-81, 2016.
[13] D. Care, "Standards of medical care in diabetes 2019," Diabetes Care, vol. 42, no. Suppl 1, pp. S124-38, 2019.
[14] C. Burballa et al., "MDRD or CKD-EPI for glomerular filtration rate estimation in living kidney donors," Nefrología (English Edition), vol. 38, no. 2, pp. 207-212, 2018.
[15] A. D. Association, "2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2021," Diabetes care, vol. 44, no. Supplement_1, pp. S15-S33, 2021.
[16] J. A. Hirst et al., "Impact of a single eGFR and eGFR-estimating equation on chronic kidney disease reclassification: a cohort study in primary care," British Journal of General Practice, vol. 68, no. 673, pp. e524-e530, 2018.
[17] A. S. Levey et al., "Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)," Kidney international, vol. 67, no. 6, pp. 2089-2100, 2005.
[18] N. M. Selby and M. W. Taal, "An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines," Diabetes, Obesity and Metabolism, vol. 22, pp. 3-15, 2020.
[19] A. J. Hahr and M. E. Molitch, "Management of diabetes mellitus in patients with chronic kidney disease," Clinical diabetes and endocrinology, vol. 1, pp. 1-9, 2015.
[20] B. A. Abed and G. S. Hamid, "Evaluation of lipocalin-2 and vaspin levels in Iraqi women with type 2 diabetes mellitus," Iraqi Journal of Science, pp. 4650-4658, 2022.
[21] P. McFarlane, R. E. Gilbert, L. MacCallum, P. Senior, and C. D. A. C. P. G. E. Committee, "Chronic kidney disease in diabetes," Canadian journal of diabetes, vol. 37, pp. S129-S136, 2013.
[22] R. Pecoits-Filho et al., "Interactions between kidney disease and diabetes: dangerous liaisons," Diabetology & metabolic syndrome, vol. 8, pp. 1-21, 2016.
[23] N. Nata, R. Rangsin, O. Supasyndh, and B. Satirapoj, "Impaired glomerular filtration rate in type 2 diabetes mellitus subjects: a Nationwide Cross‐Sectional Study in Thailand," Journal of Diabetes Research, vol. 2020, no. 1, p. 6353949, 2020.
[24] H. K. Jaid, F. M. Khaleel, I. N. Salman, and B. A. Abd, "Evaluation of insulin resistance and glutathione-s-transferase in Iraqi patients with type 2 diabetes mellitus and diabetic peripheral neuropathy," Ibn AL-Haitham Journal For Pure and Applied Sciences, vol. 35, no. 4, pp. 194-205, 2022.
[25] S. Rudberg, R. Østerby, G. Dahlquist, G. Nyberg, and B. Persson, "Predictors of renal morphological changes in the early stage of microalbuminuria in adolescents with IDDM," Diabetes Care, vol. 20, no. 3, pp. 265-271, 1997.
[26] N. U. G. Mohammed, F. M. Khaleel, and F. I. Gorial, "The role of serum chitinase-3-like 1 protein (YKL-40) level and its correlation with proinflammatory cytokine in patients with rheumatoid arthritis," Baghdad Science Journal, vol. 19, no. 5, pp. 1014-1014, 2022.
[27] N. Harita et al., "Lower serum creatinine is a new risk factor of type 2 diabetes: the Kansai healthcare study," Diabetes care, vol. 32, no. 3, pp. 424-426, 2009.
[28] N. Amartey, K. Nsiah, and F. Mensah, "Plasma levels of uric acid, urea and creatinine in diabetics who visit the Clinical Analysis Laboratory (CAn-Lab) at Kwame Nkrumah University of Science and Technology, Kumasi, Ghana," Journal of clinical and diagnostic research: JCDR, vol. 9, no. 2, p. BC05, 2015.
[29] G. Kanwar, N. Jain, N. Sharma, M. Shekhawat, J. Ahmed, and R. Kabra, "Significance of serum urea and creatinine levels in type 2 diabetic patients," IOSR J Dent Med Sci, vol. 14, no. 8, pp. 65-7, 2015.
[30] G. Bhoite, P. Bulakh, A. Kuvalekar, and A. Momin, "Association of Albumin to Creatinine Ratio with Cardiovascular Risk Markers and Determination of Their Cut off Points in Type 2 Diabetic Nephropathy Patients."
[31] N. Al Jameil, "Assessment of Blood Urea Nitrogen (BUN) and Creatinine As Biochemical Markers in Chronic Kidney Disease and End Stage Renal Disease Patients Undergoing Hemodialysis," 2019.
[32] A. Chutani and S. Pande, "Correlation of serum creatinine and urea with glycemic index and duration of diabetes in Type 1 and Type 2 diabetes mellitus: A comparative study," National journal of physiology, pharmacy and pharmacology, vol. 7, no. 9, p. 914, 2017.
[33] R. VinodMahato et al., "Association between glycaemic control and serum lipid profile in type 2 diabetic patients: Glycated haemoglobin as a dual biomarker," Biomedical Research (0970-938X), vol. 22, no. 3, 2011.
[34] N. U. G. Mohammed, F. M. Khaleel, and F. I. Gorial, "Cystatin D as a new diagnostic marker in rheumatoid arthritis," Gene Reports, vol. 23, p. 101027, 2021.
[35] J. Skupien, J. H. Warram, A. M. Smiles, R. C. Stanton, and A. S. Krolewski, "Patterns of estimated glomerular filtration rate decline leading to end-stage renal disease in type 1 diabetes," Diabetes care, vol. 39, no. 12, pp. 2262-2269, 2016.
[36] H. Belguith, "Use of e-GFR formula to evaluate kidney function in diabetes mellitus patients in Al-Jouf area, Saudi Arabia," J Biomed Sci, vol. 1, no. 1, p. 2, 2012.
Downloads
Published
License
Copyright (c) 2025 University of Thi-Qar Journal of Science
This work is licensed under a Creative Commons Attribution 4.0 International License.
